Management of tumor lysis syndrome in adults

Expert Review of Anticancer Therapy

Volumn 7, Issue 2, 2007, Pages 233-239

  Coiffier, Bertrand ^a   Riouffol, Catherine ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Allopurinol; Hyperuricemia; Rasburicase; Tumor lysis syndrome

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BICARBONATE; CAPECITABINE; CYTOTOXIC AGENT; CYTOTOXIC ANTIBODY; DIURETIC AGENT; HYPOXANTHINE; MERCAPTOPURINE; PHOSPHORUS; RASBURICASE; URATE OXIDASE; URIC ACID; URICOZYME; XANTHINE;

ACUTE KIDNEY FAILURE; ALKALINIZATION; ANAPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERURICEMIA; INCIDENCE; METHEMOGLOBINEMIA; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; TUMOR LYSIS SYNDROME;

ADULT; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 33847116219     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.2.233     Document Type: Review

References (51)

1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol 127, 3-11 (2004).
2. Michallet AS, Tartas S, Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support. Cancer Ther. 2, 159-166 (2005).
3. Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition and alternative treatment approaches. Clin. Adv. Hematol. Oncol. 3, 54-61 (2005).
4. Arrambide K, Toto RD. Tumor lysis syndrome. Semin. Nphrol. 13, 273-280 (1993).
5. Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin. Chim. Acta 333, 13-18 (2003).
6. Cohen LF, Balow JE, Macgrath IT et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am. J. Med. 68, 486-491 (1980).
7. Stapleton FB, Strother DR, Roy S 3rd et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B-cell acute lymphoblastic lymphoma. Pediatrics 82, 863-869 (1988).
8. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin. Lymphoma 3, 225-232 (2003).
9. Jeha S. Tumor lysis syndrome. Semin. Hematol. 38, 4-8 (2001).
10. Annemans L, Moeremans K, Lamotte M et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk. Lymph. 44, 77-83 (2003).
11. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183-1190 (2003).
12. Frei E 3rd, Bentzel CJ, Rieselbach R, Block JB. Renal complications of neoplastic disease. J. Chronic Dis. 16, 757-776 (1963).
13. Nicolin G. Emergencies and their management. Eur. J. Cancer 38, 1365-1377 (2002).
14. Zusman J, Brown DM, Nesbit ME. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N. Engl. J. Med. 289, 1335-1340 (1973).
15. Levine AM. Challenges in the management of Burkitt's lymphoma. Clin. Lymphoma 3(Suppl. 1), S19-S25 (2002).
16. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother. Pharmacol. 51, 187-192 (2003).
17. Ravindranath Y. Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr. Opin. Oncol. 15, 23-35 (2003).
18. Cheson BD, Frame JN, Vena D et al. Tumor lysis syndrome - an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J. Clin. Oncol. 16, 2313-2320 (1998).
19. Hussain K, Mazza JJ, Clouse LH. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am. J. Hematol. 72, 212-215 (2003).
20. Boccia RV, Longo DL, Lieber ML et al. Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma. Cancer 56, 2295-2297 (1985).
21. Sallan S. Management of acute tumor lysis syndrome. Semin. Oncol. 28, 9-12 (2001).
22. Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 25, 1820-1825 (2005).
23. Hogan DK, Rosenthal LD. Oncologic emergencies in the patient with lymphoma. Semin. Oncol. Nurs. 14, 312-320 (1998).
24. Navolanic PM, Pui CH, Larson RA et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a meeting report, Dallas, Texas, January 2002. Leukemia 17, 499-514 (2003).
25. Linck D, Basara N, Tran V et al. Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. Bone Marrow Transplant. 31, 935-937 (2003).
26. Patte C, Sakiroglu C, Ansoborlo S et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann. Oncol. 13, 789-795 (2002).
27. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr. Nephrol. 9, 206-212 (1995).
28. Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA 193, 1-6 (1965).
29. Goldman SC, Holcenberg JS, Finklestein JZ et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97, 2998-3003 (2001).
30. Andreoli SP, Clark JH, McGuire WA, Bergstein JM. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J. Pediatr. 109, 292-298 (1986).
31. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann. Pharmacother. 27, 337-343 (1993).
32. Smalley RV, Guaspari A, Haase-Statz S et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J. Clin. Oncol. 18, 1758-1763 (2000).
33. Dervieux T. Brenner TL, Hon YY et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 100, 1240-1247 (2002).
34. Yeldandi AV, Yeldandi V, Kumar S et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 109, 281-284 (1991).
35. Laboureur P, Langlois C. Urate oxydase d'Aspergillus flavus. II. Métabolisme, inhibitions, spécificité. Bull. Soc. Chim. Biol. 50, 827-841 (1968).
36. Kissel P. Lamarche M, Royer R. Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature 217, 72-74 (1968).
37. Masera G, Jankovic M, Zurlo MG et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J. Pediatr. 100, 152-155 (1982).
38. Pui CH, Relling MV, Lascombes F et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11, 1813-1816 (1997).
39. Patte C, Sakiroglu O, Sommelet D. European experience in the treatment of hyperuricemia. Semin. Hematol. 38, 9-12 (2001).
40. Pui CH, Mahmoud HH, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J. Clin. Oncol. 19, 697-704 (2001).
41. Coiffier B, Mounier N, Bologna S et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 study. J. Clin. Oncol. 21, 4402-4406 (2003).
42. Bosly A, Sonet A, Pinkerton CR et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 98, 1048-1054 (2003).
43. Jeha S, Pui CH. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib. Nephrol, 147, 69-79 (2005).
44. Annemans L, Moeremans K, Lamotte M et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support. Care Cancer 11, 249-257 (2003).
45. Hummel M, Buchheidt D, Reiter S et al. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 17, 2542-2544 (2003).
46. Trifilio, S, Gordon L, Singhal S et al. Reduced-dose rasbuticase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 37, 997-1001 (2006).
47. Hummel M, Buchheidt D, Reiter S et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur. J. Haematol. 75, 518-521 (2005).
48. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmarotherapy 26, 242-247 (2006).
49. Liu CY, Sims-McCallum RP. Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk. Res. 29, 463-465 (2005).
50. Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J. Support. Oncol, 3, 117-124 (2005).
51. Wang LY, Shih LY, Chang H et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol. 115, 35-38 (2006).